MTOR and metabolic syndrome: On the other hand, dyslipidemia including increased total cholesterol, LDL cholesterol and triglyceride, often occurred when utilizing mTOR inhibitors; this is a main risk factor of atherosclerosis (Kasiske et al., 2008; Kurdi, Martinet & De Meyer, 2018).